Paying users zone. Data is hidden behind: .
Get 1-month access to Eli Lilly & Co. for $19.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Eli Lilly & Co. pages available today for free:
Enterprise Value to FCFF (EV/FCFF)
Free Cash Flow to The Firm (FCFF)
Eli Lilly & Co., FCFF calculation
US$ in thousands
Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21).
1, 2 See details »
Item | Description | The company |
---|---|---|
FCFF | Free cash flow to the firm is the cash flow available to the Eli Lilly & Co.’s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. | Eli Lilly & Co.’s FCFF decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level. |
Interest Paid, Net of Tax
Eli Lilly & Co., interest paid, net of tax calculation
US$ in thousands
Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21).
2 2020 Calculation
Cash payments for interest on borrowings, tax = Cash payments for interest on borrowings × EITR
= × =
3 2020 Calculation
Interest costs capitalized, tax = Interest costs capitalized × EITR
= × =
Enterprise Value to FCFF Ratio, Current
Eli Lilly & Co., current EV/FCFF calculation, comparison to benchmarks
Selected Financial Data (US$ in thousands) | |
Enterprise value (EV) | |
Free cash flow to the firm (FCFF) | |
Valuation Ratio | |
EV/FCFF | |
Benchmarks | |
EV/FCFF, Competitors1 | |
Abbott Laboratories | |
AbbVie Inc. | |
Amgen Inc. | |
Bristol-Myers Squibb Co. | |
Gilead Sciences Inc. | |
Illumina Inc. | |
Johnson & Johnson | |
Merck & Co. Inc. | |
Pfizer Inc. | |
Regeneron Pharmaceuticals Inc. | |
Vertex Pharmaceuticals Inc. | |
Zoetis Inc. | |
EV/FCFF, Sector | |
Pharmaceuticals & Biotechnology | |
EV/FCFF, Industry | |
Health Care |
Based on: 10-K (filing date: 2021-02-17).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Eli Lilly & Co., historical EV/FCFF calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Enterprise value (EV)1 | ||||||
Free cash flow to the firm (FCFF)2 | ||||||
Valuation Ratio | ||||||
EV/FCFF3 | ||||||
Benchmarks | ||||||
EV/FCFF, Competitors4 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
EV/FCFF, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
EV/FCFF, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21).
3 2020 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/FCFF | Enterprise value to free cash flow to the firm is whole company valuation indicator. | Eli Lilly & Co.’s EV/FCFF ratio increased from 2018 to 2019 and from 2019 to 2020. |